Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 16, 2026, 9:14 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 8,256 matching trials from the live ClinicalTrials.gov search.
Recruiting Not applicable Interventional Accepts healthy volunteers

Cognitive Strategies for Weight Loss

NCT05799846
Conditions
Obesity
Interventions
Standard Behavioral Weight Loss Intervention, PREVENT Behavioral Weight Loss Intervention, PROMOTE Behavioral Weight Loss Intervention
Behavioral
Lead sponsor
The Miriam Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
360 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Providence, Rhode Island
Conditions
Hematologic Malignancies
Interventions
CliniMACS® CD34 Reagent System, Fludarabine, Melphalan, anti-thymocyte globulin (rabbit), Rituximab, Total Body Irradiation, Mycophenolate Mofetil, Tacrolimus
Device · Drug · Radiation
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
2
States / cities
Chicago, Illinois • New York, New York
Conditions
Gestational Weight Gain
Interventions
Lifestyle Intervention
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
21 Years to 45 Years · Female only
Enrollment
1,335 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
4
States / cities
Oakland, California • Redwood City, California • San Francisco, California + 1 more
Conditions
Breast Cancer, Colorectal Cancer, Endometrial Cancer, Kidney Cancer, Multiple Myeloma, Ovary Cancer, Prostate Cancer, Thyroid Cancer, Non-Hodgkin Lymphoma
Interventions
Adapting MultiPLe Behavior Interventions That eFfectively Improve (AMPLIFI) Cancer Survivor Health, Diet-Exercise, Exercise-Diet, Combined Diet and Exercise
Behavioral · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
50 Years and older
Enrollment
603 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
2
States / cities
Birmingham, Alabama • Memphis, Tennessee
Conditions
Renal Failure, Protein-Energy Malnutrition
Interventions
Whey protein supplement
Dietary Supplement
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
2
States / cities
Gainesville, Florida
Conditions
Antithrombotic
Interventions
Enoxaparin, unfractionated heparin (UFH), BMS-986177
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
3
States / cities
Lakewood, Colorado • Orlando, Florida • Minneapolis, Minnesota
Conditions
SLE, Lupus, Systemic Lupus Erthematosus, Systemic Lupus Erythematosus, Systemic Lupus Erythematosus (SLE)
Interventions
Physical examination, Electrocardiogram, SF-36 questionnaire, Clinical laboratory evaluations - Serology, Clinical laboratory evaluations - Biochemistry, Clinical laboratory evaluations - Hematology, Pregnancy Test, Urinalysis, SLE activity evaluation, SLE biomarker profiling, Cytokines and chemokine profiling, single dose of UC-MSCs, PROMIS instruments
Diagnostic Test · Other · Biological
Lead sponsor
LiveKidney.Bio
Industry
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Charleston, South Carolina
Conditions
Alzheimer's Disease
Interventions
[18F]RO6958948
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
25 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Enterocolitis, Necrotizing, Intestinal Perforation
Interventions
Not listed
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
Up to 6 Weeks
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
17
States / cities
Birmingham, Alabama • Palo Alto, California • San Diego, California + 13 more
Completed Phase 3 Interventional

Latino Semaglutide Study

NCT05087342
Conditions
Obesity, Obesity; Drug, Overweight or Obesity, Weight Loss, Weight Loss Trajectory, Weight, Body
Interventions
Semaglutide 2.4mg, Placebo
Drug
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years to 75 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Loma Linda, California
Conditions
Mild Cognitive Impairment, Accidental Falls, Aging
Interventions
dual-task tai ji quan, standard tai ji quan, stretching
Behavioral
Lead sponsor
Oregon Research Institute
Other
Eligibility
65 Years to 95 Years
Enrollment
336 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Springfield, Oregon
Completed Phase 1 Interventional Results available

A Phase 1b Trial in Patients With Renal Cell Cancer

NCT01258348
Conditions
Metastatic Renal Cell Cancer
Interventions
Drug: LY573636-sodium, Sunitinib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
4
States / cities
Indianapolis, Indiana • Greenville, South Carolina • The Woodlands, Texas + 1 more
Completed Phase 3 Interventional Results available

Contrast-enhanced MRI in Children 2 Months to <2 Years

NCT00937391
Conditions
Magnetic Resonance Imaging
Interventions
Gadopentetate dimeglumine (Magnevist, BAY86-6661)
Drug
Lead sponsor
Bayer
Industry
Eligibility
2 Months to 23 Months
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
9
States / cities
San Diego, California • Aurora, Colorado • Chicago, Illinois + 6 more
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Does Dapagliflozin Promote Favorable Health Benefits That Are Independent Of Weight Loss?

NCT02520518
Conditions
Weight Loss
Interventions
Dapagliflozin, Placebo, Weight maintenance, Ad libitum dietary intake, Dietary restriction
Drug · Behavioral
Lead sponsor
Christopher Bell
Other
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Fort Collins, Colorado
Completed Not applicable Interventional Accepts healthy volunteers Results available

Phone Coaching for Weight Loss Maintenance

NCT04293055
Conditions
Obesity, Weight Loss
Interventions
Maintenance program, Phone coaching
Behavioral
Lead sponsor
The Miriam Hospital
Other
Eligibility
18 Years to 72 Years
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Providence, Rhode Island
Completed Not applicable Interventional Accepts healthy volunteers

Substituting Mushrooms for Meat to Control Body Weight

NCT01177085
Conditions
Obesity
Interventions
Weight-loss and weight-maintenance diets
Behavioral
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Venous Thrombosis
Interventions
Enoxaparin
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Stanford, California
Conditions
Chronic Inflammatory Demyelinating Polyneuropathy, Polyradiculoneuropathy
Interventions
IgPro20 (low dose), Placebo, IgPro10, IgPro20 (high dose)
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
22
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 16 more
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Intraoperative Low-dose Ketamine Infusion for Patients With Obstructive Sleep Apnea

NCT03109418
Conditions
Sleep Apnea, Obstructive Sleep Apnea, Postoperative Complications
Interventions
Ketamine, Control
Drug · Procedure
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 100 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Obesity
Interventions
Acceptance and Commitment Therapy-Based Physical Activity Intervention, Physical Activity Education Control
Behavioral
Lead sponsor
Hartford Hospital
Other
Eligibility
18 Years to 64 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Hartford, Connecticut
Conditions
Diabetes, Obesity, Weight Gain
Interventions
Lifestyle Balance
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 70 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
3
States / cities
Long Beach, California • Sepulveda, California • West Los Angeles, California
Conditions
Autosomal Recessive Polycystic Kidney (ARPKD)
Interventions
Tolvaptan Suspension, Tolvaptan Tablets
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
28 Days to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
12
States / cities
Washington D.C., District of Columbia • Atlanta, Georgia • Chicago, Illinois + 9 more
Conditions
Breast Cancer
Interventions
Lifestyle intervention, Mail-based
Behavioral
Lead sponsor
Ontario Clinical Oncology Group (OCOG)
Other
Eligibility
Female only
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
4
States / cities
Torrance, California • Boston, Massachusetts • Seattle, Washington